KR900700153A - 생리학적 활성물질 투여를 위한 폐색체 - Google Patents

생리학적 활성물질 투여를 위한 폐색체

Info

Publication number
KR900700153A
KR900700153A KR1019890701941A KR890701941A KR900700153A KR 900700153 A KR900700153 A KR 900700153A KR 1019890701941 A KR1019890701941 A KR 1019890701941A KR 890701941 A KR890701941 A KR 890701941A KR 900700153 A KR900700153 A KR 900700153A
Authority
KR
South Korea
Prior art keywords
reservoir
obturator
active substance
physiologically active
membrane
Prior art date
Application number
KR1019890701941A
Other languages
English (en)
Other versions
KR970009723B1 (ko
Inventor
존 마크 터커
마크 러퍼트 터커
Original Assignee
터커. 존 마크
마크 러퍼트 터커
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 터커. 존 마크, 마크 러퍼트 터커 filed Critical 터커. 존 마크
Publication of KR900700153A publication Critical patent/KR900700153A/ko
Application granted granted Critical
Publication of KR970009723B1 publication Critical patent/KR970009723B1/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

내용 없음

Description

생리학적 활설물질 투여를 위한 폐색체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예1의 반창고의 약횡단면도이다. 제2도 내지 7도는 3분을 주기로한 시간 200에 대한 방출 그래프이다.

Claims (16)

  1. 생리학적 활성 물질을 피부를 통해 투여하기 위한 폐색체에 잇어서, 상기 폐색체는 액체 형태의 생리학적 활성물질을 포함하는 저장소, 생리학적 활성 물질이 통과할수 있고 활성물질과 가까이 있는 미소다공질 막으로 구성된 저장소 벽, 및 저장소내의 점성의 유동겔에 의해 실제로 고정된 액체 내용물로 구성하되 a)상기 막(3)은 소수성이고, 상기 저장소는 친수성 습윤제를 포함하거나, b)상기 막(3)은 친수성이고 상기 저장소 내용물은 소수성인 생리학적 활성 물질을 피부를 통해 투여하기 위한 폐색체.
  2. 제1항에 있어서, 막(3)이 접착제(2)로 코팅된것을 특징으로 하는 폐색체.
  3. 제2항에 있어서, 접착제는 실리콘에 기초를 둔 접착제임을 특징으로 하는 폐색체.
  4. 상기 청구항중 어느 한 항에 있어서, 막(3)이 소수성이고 상기 저장소가 친수성 습윤제를 포함하는 것을 특징으로 하는 폐색체.
  5. 제4항에 있어서, 저장소 내용물은 점성도 저절제나 계면활성제 역활도 하는 가소제와 함께 무롤 구성되는 것을 특징으로 하는 폐색체.
  6. 제5항에 있어서, 계면 활성제는 메틸 셀룰로오즈로 구성되는 것을 특징으로 하는 폐색체.
  7. 제6항에 있어서, 메틸 셀룰로오즈의 양이 저장소 내용물에 관하여 무게당 약 5% 내지 6%인 것을 특징으로 하는 폐색체.
  8. 상기 청구항 중 어느 한 항에 있어서, 생리학적 활성물질이 니코틴인 것을 특징으로 하는 폐색체.
  9. 제8항에 있어서, 니코틴의 양이 저장소의 전체 액체 내용물의 무게당 2% 내지 10%인 것을 특징으로 하는 폐색체.
  10. 상기 청구항 중 어느 한 항에 있어서, 저장소 내용물이 차나무 기름을 포함하는 것을 특징으로 하는 폐색체.
  11. 제10항에 잇어서, 차나무 기름의 양이 저장소의 액체 내용물의 무게당 0.05%내지 2%인 것을 특징으로 하는 폐색체.
  12. 제1항 내지 7항 중 어느 한 항에 있어서, 생리학적 활성 물질이 파라세타몰, 에페드란, 펜타닐, 티몰올, 클로니딘, 히오스친, 에스트라디올, 프로게스테론, 살부타몰, 또는 테스토스테론인 것을 특징으로 하는 폐색체.
  13. 상기 청구항 중 어느 한 항에 있어서, 저장소가 금속 또는 플라스틱 엷은 판으로 된 불침투성 뒷받침(4)로 구성되는 것을 특징으로 하는 폐색체.
  14. 상기 청구항 중 어느 한 항에 있어서, 상기 생리학적 활성 물질이 저장소 내용물의 무게당 25%이상을 차지하지 않기 위하여 적어도 하나의 희석제와 함께 존재하는 것을 특징으로 하는 폐색체.
  15. 상기 청구항 중 어느 한 항에 있어서, 상기 저장소의 벽이 미소다공질 막의 외부 표면과 가까이 있는 침투성 막으로 구성되어 있고, 상시 침투성 막이 상기 미소다공질 막(3)의 습윤력과 같거나 다른 습윤력을 가지는 것을 특징으로 하는 폐색체.
  16. 폐색체가 액체 형태의 활성 물질을 포함하는 저장소, 활성 물질이 침투할수 있는 저장소 벽(3) 및, 차나무 기름이나 그의 주요성분을 부가적으로 포함하는 저장소로 구성된 것을 특징으로 하는 생리학적 활성 물질을 피부로 통해 투여하기 위한 폐색체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890701941A 1988-02-23 1989-02-23 생리학적 활성물질의 경피성 투여용 폐색체 KR970009723B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8804164 1988-02-23
GB888804164A GB8804164D0 (en) 1988-02-23 1988-02-23 Bandage for administering physiologically active compound
GB?88-04164? 1988-02-23
PCT/GB1989/000185 WO1989007959A1 (en) 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance

Publications (2)

Publication Number Publication Date
KR900700153A true KR900700153A (ko) 1990-08-11
KR970009723B1 KR970009723B1 (ko) 1997-06-17

Family

ID=10632193

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890701941A KR970009723B1 (ko) 1988-02-23 1989-02-23 생리학적 활성물질의 경피성 투여용 폐색체

Country Status (11)

Country Link
US (1) US5254346A (ko)
EP (2) EP0508979B1 (ko)
JP (1) JP2716231B2 (ko)
KR (1) KR970009723B1 (ko)
AU (1) AU618085B2 (ko)
DE (1) DE68915291T2 (ko)
ES (1) ES2052071T3 (ko)
GB (1) GB8804164D0 (ko)
IN (1) IN172748B (ko)
WO (1) WO1989007959A1 (ko)
ZA (1) ZA891403B (ko)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
JPH02149514A (ja) * 1988-04-06 1990-06-08 Nitto Denko Corp 医薬部材
DE69108136T2 (de) * 1990-08-03 1995-11-02 Terumo Corp Wundabdeckmaterial.
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5240917A (en) * 1991-04-03 1993-08-31 Keimowitz Rudolph M Suppression of thromboxane levels by percutaneous administration of aspirin
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
CH686816A5 (de) * 1992-02-04 1996-07-15 Asulab Ag Einrichtung zur Abgabe eines Arzneimittels.
US6071896A (en) * 1992-06-16 2000-06-06 Gundersen Clinic, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
DE9219105U1 (de) * 1992-10-31 1998-03-05 Klocke Verpackungs-Service GmbH, 76356 Weingarten Behälter zur Aufnahme von aromatischen Substanzen
DE69333009T2 (de) * 1992-11-09 2003-12-04 Neurogesx, Inc. Transdermale verabreichung von ketorolac
FR2709670B1 (fr) * 1993-09-10 1995-10-20 Asulab Sa Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse.
ATE246909T1 (de) * 1994-03-07 2003-08-15 Theratech Inc Medikament enthaltende, adhesive, zusammenbaubare,transdermale abgabevorrichtung
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6119036A (en) * 1997-03-26 2000-09-12 The Board Of Regents Of The University Of Oklahoma Iontophoretic transdermal delivery device
US5919476A (en) * 1997-09-29 1999-07-06 Pmt Corporation Reinforced gel sheeting for scar treatment
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
WO1999061007A1 (de) * 1998-05-22 1999-12-02 Novosis Pharma Ag Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
ATE438418T1 (de) 2001-05-01 2009-08-15 Av Topchiev Inst Petrochemical Hydrogel-zusammensetzungen
RU2286801C2 (ru) 2001-05-01 2006-11-10 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Двухфазные биоадгезионные композиции, абсорбирующие воду
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2492654A1 (en) * 2002-07-16 2004-01-22 University Of South Florida Human immunosuppressive protein
EP2130541A3 (en) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2003291037A1 (en) 2002-11-18 2004-06-15 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
CA2453013C (en) * 2002-12-13 2011-02-15 Gary W. Cleary Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
US20060246104A1 (en) * 2003-04-16 2006-11-02 Massia Stephen P Stable rgd peptidomimetic composition
WO2004093788A2 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
EP1648363B1 (en) 2003-07-03 2019-03-06 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
DE602004032446D1 (de) 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
EP1663168B1 (en) * 2003-09-08 2009-02-11 McNeil AB Nicotine formulations and use thereof
EP1713450B1 (en) 2004-01-30 2021-10-06 Corium, Inc. Rapidly dissolving film for delivery of an active agent
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
CA2557532A1 (en) 2004-04-23 2005-11-10 Angela M. Christiano Inhibition of hairless protein mrna
US20050249791A1 (en) * 2004-05-07 2005-11-10 3M Innovative Properties Company Antimicrobial articles
GB2414461B (en) * 2004-05-24 2007-09-12 Mark Rupert Tucker Form-fill-seal process
KR20070048229A (ko) 2004-08-05 2007-05-08 코리움 인터네셔널, 인크. 접착제 조성물
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US20060079514A1 (en) * 2004-10-13 2006-04-13 Victory Pharma Incorporated Methods and compositions including methscopolamine bromide
US20060079513A1 (en) * 2004-10-13 2006-04-13 Preston David M Methods and compositions including methscopolamine nitrate
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
NZ582975A (en) 2004-10-21 2011-07-29 Durect Corp Transdermal delivery systems delivering sufentanil
GB2421431B (en) * 2004-12-24 2007-10-10 Aquasol Ltd Dosing systems
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
EP1965777A1 (en) * 2005-12-08 2008-09-10 Fertin Pharma Transdermal tobacco alkaloid patch
US20090169606A1 (en) * 2005-12-08 2009-07-02 Fertin Pharma Low Flexural Strength Transdermal Tobacco Alkaloid Patch
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
JP5386180B2 (ja) 2006-02-28 2014-01-15 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 真皮細胞のコンパクト凝集のための方法
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
DK2054031T3 (en) 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Wnt信号伝達に関係した分泌タンパク質
EP2089369B1 (en) 2006-10-19 2011-02-02 Rigel Pharmaceuticals, Inc. 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
JP5264759B2 (ja) 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
US7820207B2 (en) 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
AU2007353989A1 (en) * 2007-05-31 2008-12-04 Fertin Pharma A/S Transdermal tobacco alkaloid reservoir patch
US8034983B2 (en) * 2007-06-06 2011-10-11 Multi-Tech Specialty Chemicals, Co., Ltd. Process for the preparation of xanthophyll crystals
CA2694325C (en) 2007-07-30 2015-09-22 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
EP2278879B1 (en) * 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
RS54413B1 (en) * 2008-08-22 2016-04-28 Sanofi [4- (5-AMINOMETHYL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - [7-FLUORO-1- (2-METHOXY-ETHYL) -4TRIFLUOROMETOXY-1H-INDOL-3-IL] METHANONE AS INHIBITOR MASTOCYT TRIPTASES
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2010078369A2 (en) 2008-12-30 2010-07-08 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
EP2387394B1 (en) 2009-01-14 2018-05-02 Corium International, Inc. Transdermal administration of tamsulosin
PT2389372E (pt) 2009-01-23 2016-01-07 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
EP3620154A1 (en) 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
CA2766643C (en) 2009-07-08 2017-01-03 Dermira (Canada), Inc. Tofa analogs useful in treating dermatological disorders or conditions
US20110034415A1 (en) 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
WO2011022371A2 (en) * 2009-08-17 2011-02-24 Silipos Inc. Gel product
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
CN102770431A (zh) 2009-12-23 2012-11-07 赛诺菲 [4[4-(5-氨基甲基-2-氟-苯基)-哌啶-1-基]-(1h-吡咯并吡啶-基)-甲酮及其合成
JP2013515732A (ja) 2009-12-23 2013-05-09 サノフイ [4[4−(5−アミノメチル−2−フルオロ−フェニル)−ピペリジン−1−イル]−(1h−ピロロ−ピリジン−イル)−メタノンのプロドラッグ及びその合成
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
WO2011133600A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
CN103096889A (zh) 2010-04-20 2013-05-08 寰宇一家健康研究所 包含1,3,4-噁二唑衍生物的化合物、组合物和方法
BR112012027308B1 (pt) 2010-04-24 2021-07-06 Mycovia Pharmaceuticals, Inc. compostos inibidores de metaloenzima e composições compreendendo os mesmos
US20120208855A1 (en) 2010-07-12 2012-08-16 Sanofi Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
CN103201280B (zh) 2010-07-28 2016-08-10 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US9056855B2 (en) 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103370076A (zh) 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CN106243051B (zh) 2010-11-13 2019-03-08 茵库恩制药有限公司 金属酶抑制剂化合物
BR112013014484A2 (pt) 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc compostos inibidores de metaloenzimas
JP2013545800A (ja) 2010-12-20 2013-12-26 コルゲート・パーモリブ・カンパニー 親水性活性剤、疎水性構造化剤および油担体を含有するゼラチンカプセル化された口腔ケア組成物
WO2012116254A2 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
WO2012177608A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
UA114090C2 (uk) 2011-06-19 2017-04-25 Вайамет Фармасьютікалс, Інк. Сполуки, що інгібують металоферменти
AU2012273007A1 (en) 2011-06-23 2014-01-30 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
US8703177B2 (en) 2011-08-18 2014-04-22 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
EP2750767A4 (en) 2011-09-02 2015-10-14 Univ Columbia INHIBITORS OF CAMKII, IP3R, CALCINEURIN, P38 AND MK2 / 3 TO TREAT METABOLIC DISTURBANCES OF OBESITY
US9309273B2 (en) 2011-12-11 2016-04-12 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
ES2774267T3 (es) 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
JP6231548B2 (ja) 2012-03-23 2017-11-15 マテオン セラピューティクス, インコーポレイテッド カテプシンの阻害のための組成物および方法
HUE040127T2 (hu) 2012-03-29 2019-02-28 Univ Columbia Eljárások hajhullási rendellenességek kezelésére
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
JP2016506930A (ja) 2013-01-25 2016-03-07 ライジェル ファーマシューティカルズ, インコーポレイテッド 炎症性腸疾患を処置するための化合物および方法
CA2907152A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20150157509A1 (en) * 2013-12-11 2015-06-11 Oscar Polk Atkinson Occlusive skin covering
US20150174386A1 (en) * 2013-12-19 2015-06-25 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
MX2016011517A (es) 2014-03-07 2017-04-13 Univ Arizona Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico.
EP3119746A4 (en) 2014-03-19 2017-08-16 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3925979A3 (en) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
US9840492B2 (en) 2015-03-19 2017-12-12 Viamet Pharmaceuticals, Inc. Antifungal compounds and processes for making
EP3719016A1 (en) 2015-08-04 2020-10-07 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
ES2821021T3 (es) 2015-09-18 2021-04-23 Nqp 1598 Ltd Procedimiento de compuestos antifúngicos
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
KR102240920B1 (ko) 2015-12-30 2021-04-16 브이피에스-3, 엘엘씨 금속 효소 억제 화합물
JP6960937B2 (ja) 2016-03-08 2021-11-05 リビング プルーフ インコーポレイテッド 長期持続性化粧品組成物
ES2940911T3 (es) 2016-06-27 2023-05-12 Rigel Pharmaceuticals Inc Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
EP3478091B1 (en) 2016-06-29 2024-03-20 Halo Life Science, LLC Method of preparing a low odor dicholinium ellagate salt and other low odor organic salts of choline
CA3041587A1 (en) 2016-10-26 2018-05-17 Rigel Pharmaceuticals, Inc. Oxazole derivatives for use as irak inhibitors and method for their preparation
CN110234637B (zh) 2016-10-26 2022-11-01 里格尔药品股份有限公司 用作irak抑制剂的吡唑酰胺化合物
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
EP3562487B1 (en) 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
GB201708579D0 (en) * 2017-05-30 2017-07-12 Univ Of Wolverhampton Science Park Ltd Wound dressing
JP7167069B2 (ja) 2017-06-29 2022-11-08 ライジェル ファーマシューティカルズ, インコーポレイテッド キナーゼ阻害剤ならびに作製および使用のための方法
GB2561262B (en) * 2017-07-13 2019-03-20 Dentmed Ltd A targeted drug delivery pad
US10842729B2 (en) 2017-09-13 2020-11-24 Living Proof, Inc. Color protectant compositions
JP7244495B2 (ja) 2017-09-13 2023-03-22 リビング プルーフ インコーポレイテッド 長期持続性の化粧品組成物
CA3084488A1 (en) 2017-11-20 2019-05-23 Living Proof, Inc. Properties for achieving long-lasting cosmetic performance
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
JOP20200277A1 (ar) 2018-05-03 2020-11-03 Rigel Pharmaceuticals Inc مركبات تثبيط rip1 وطرق لتحضير واستخدامها
CA3099037A1 (en) 2018-05-03 2019-11-07 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US11090346B2 (en) 2019-05-28 2021-08-17 Inbold Inc. Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
CN114698370A (zh) 2019-08-08 2022-07-01 里格尔药品股份有限公司 用于治疗细胞因子释放综合征的化合物和方法
CA3147444A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
WO2021041898A1 (en) 2019-08-30 2021-03-04 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
EP4055021A1 (en) 2019-11-07 2022-09-14 Rigel Pharmaceuticals, Inc. Heterocyclic rip1 inhibitory compounds
US20220288047A1 (en) 2021-03-03 2022-09-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
WO2023136749A1 (ru) * 2022-01-11 2023-07-20 Павел Владимирович КОРЧАГИН Система и способ обеспечения безопасности для держателей банковских карт
WO2023183377A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
US20230312568A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
ZA761193B (en) * 1975-03-19 1977-02-23 Procter & Gamble Controlled release articles
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
DE3587616D1 (de) * 1984-12-22 1993-11-11 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
GB8512358D0 (en) * 1985-05-16 1985-06-19 Euro Celtique Sa Transdermal delivery system

Also Published As

Publication number Publication date
EP0336543A1 (en) 1989-10-11
DE68915291D1 (de) 1994-06-16
JP2716231B2 (ja) 1998-02-18
ES2052071T3 (es) 1994-07-01
GB8804164D0 (en) 1988-03-23
EP0508979B1 (en) 1994-05-11
DE68915291T2 (de) 1994-09-01
EP0508979A1 (en) 1992-10-21
ZA891403B (en) 1989-11-29
AU618085B2 (en) 1991-12-12
JPH03503636A (ja) 1991-08-15
US5254346A (en) 1993-10-19
IN172748B (ko) 1993-11-20
AU3289589A (en) 1989-09-22
WO1989007959A1 (en) 1989-09-08
KR970009723B1 (ko) 1997-06-17

Similar Documents

Publication Publication Date Title
KR900700153A (ko) 생리학적 활성물질 투여를 위한 폐색체
KR950007808A (ko) 약물투여용 의료용구
KR910016318A (ko) 이온 전기 도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법 및 여기에 사용되는 조성물
KR890701164A (ko) 피부침투성 치료 시스템
KR930703038A (ko) 증대된 약제 유량을 나타내는 아포화된 경피적 약제 전달장치
KR900701274A (ko) 남용 가능성을 감소시킨 용량 제형
KR890011585A (ko) 경피식 피임약제제형
DE69925936D1 (de) Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
HUP0200315A2 (en) Non-invasive vaccination through the skin
KR880012216A (ko) 활성성분 배합물용 경피성 치료계
IE882898L (en) Solubility modulated drug delivery device
EP0922453A3 (en) Percutaneous absorption type preparation containing tulobuterol
JPS59186564A (ja) 投薬装置
JPH0324119U (ko)
DE69121881D1 (de) Hautelektrodenaufbau und dazugehöriges gerät zur transdermalen verabreichung von heilmitteln
KR900005969A (ko) 게스토덴을 함유하는 경피 투여용 제제
DK0674913T3 (da) Ikke-okklusivt klæbende plaster til påföring af medicament i huden
KR870005652A (ko) 다구획화된 피부 및 경피용 패치
ATE63059T1 (de) Vorrichtung mit zwei schichten zur freisetzung von arzneimitteln.
JPS6485912A (en) User-activating transdermal treatment system
CA2010225A1 (en) Therapeutic System for the Retarded and Controlled Transdermal or Transmucous Administration of Active Substances (1)
JPS56100716A (en) Drug administration member
KR100260323B1 (ko) 약액을구비한일회용밴드
JPS52156932A (en) Remedy for diabetes
ATE205406T1 (de) Hauthaftende pharmazeutische zubereitung, insbesondere tts zur abgabe von 17-beta-estradiol an den menschlichen organismus

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070406

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee